ENVERIC BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ENVERIC BIOSCIENCES, INC. (ENVB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 50.00 thousand shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2023-06-09
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-03-31 was 50.00K shares, a 91.08% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2021-12-31 was -678.63K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2021-09-30 was 132.07K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2021-06-30 was 0.00 shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 13.85K shares, a 94.38% decline from fiscal 2020.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2020 was 246.41K shares, a 27.78% decline from fiscal 2019.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2019 was 341.17K shares, a 856.44% increase from fiscal 2018.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2018 was 35.67K shares, a 217.10% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2022-03-31 | 50.00K shares 10-Q · filed 2022-05-13 | -628.63K shares derived: sum of 2 quarters · filed 2023-06-09 | -496.55K shares derived: sum of 3 quarters · filed 2023-06-09 | -496.55K shares derived: sum of 4 quarters · filed 2023-06-09 | |
| 2021-12-31 | -678.63K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-09 | -546.55K shares derived: sum of 2 quarters · filed 2023-06-09 | -546.55K shares derived: sum of 3 quarters · filed 2023-06-09 | 13.85K shares 10-K/A · filed 2023-06-09 | 692.48K shares 10-K · filed 2022-03-31 |
| 2021-09-30 | 132.07K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 132.07K shares derived: sum of 2 quarters · filed 2021-11-15 | 692.48K shares 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | 560.40K shares 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | 560.40K shares 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | 246.41K shares 10-K · filed 2022-03-31 | ||||
| 2019-12-31 | 341.17K shares 10-K · filed 2021-04-01 | 32.91K shares 10-K/A · filed 2020-08-12 | |||
| 2018-12-31 | 35.67K shares 10-K/A · filed 2020-08-12 | ||||
| 2017-12-31 | 11.25K shares 10-K/A · filed 2020-08-12 | ||||
| 2016-12-31 | -48.60K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-08-12 | -48.60K shares derived: sum of 2 quarters · filed 2020-08-12 | 6.40K shares 10-K/A · filed 2020-08-12 | ||
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | 55.00K shares 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | 55.00K shares 10-Q · filed 2016-08-12 | ||||
| 2015-12-31 | 0.00 shares 10-K/A · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |